ePrints

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies

Lookup NU author(s): Emeritus Professor Philip Home

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2025 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.Aims: To estimate the relative treatment effect of iGlarLixi (a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide) versus premixed insulin IDegAsp (insulin degludec plus insulin aspart) in people with type 2 diabetes (T2D) who advanced from basal insulin to iGlarLixi or IDegAsp in non-Asian studies. Materials and Methods: Randomized controlled trials (RCTs) were identified in a systematic review by searching Embase (including congress abstracts from 2021 to 2023), MEDLINE® and CENTRAL on 10 October 2023. Treatment outcomes from non-Asian RCTs for people with T2D previously treated with basal insulin, who switched to iGlarLixi or IDegAsp, were compared using a network meta-analysis (NMA). Data analysis was performed using R, version 4.0.2. Results: The NMA included four RCTs (N = 2535). The results of the NMA showed that iGlarLixi (n = 810) was associated with a significantly greater reduction in HbA1c versus IDegAsp (n = 454) (mean difference [MD]: −0.39 [95% credible interval, CrI: −0.58, −0.21] %-units). iGlarLixi was also associated with a significantly greater likelihood of achieving an HbA1c of <7.0% (risk ratio: 1.42, 95% CrI: 1.18, 1.71). A greater reduction in postprandial glucose was observed with iGlarLixi versus IDegAsp (MD: −1.38 [95% CrI: −2.15, −0.63] mmol/L). A body weight benefit that favoured iGlarLixi versus IDegAsp was documented (MD: −1.54 [95% CrI: −2.26, −0.84] kg). Hypoglycaemia evaluation was inconclusive due to definitional differences between trials. Conclusions: Once-daily iGlarLixi was associated with superior blood glucose control and body weight benefit compared with IDegAsp in insulin-experienced populations with T2D in non-Asian RCTs.

Publication metadata

Author(s): Home P, Lauand F, Djaballah K, Li X-T, Hafidh K, Mehta R, Faraoun K, Anaforoglu I, Serafini P, Pourrahmat M-M

Publication type: Article

Publication status: Published

Journal: Diabetes, Obesity and Metabolism

Year: 2025

Volume: 27

Issue: 6

Pages: 3410-3418

Print publication date: 01/06/2025

Online publication date: 02/04/2025

Acceptance date: 12/03/2025

Date deposited: 23/04/2025

ISSN (print): 1462-8902

ISSN (electronic): 1463-1326

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/dom.16360

DOI: 10.1111/dom.16360

Data Access Statement: Data are available through the corresponding author upon reasonable request. Further details on Sanofi's data-sharing criteria, eligible studies and process for requesting access can be found at https://www.vivli.org.

Altmetrics

Funding

Share